LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company ...
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia ...
Therapy-related MDS/AML is an increasingly recognized, often fatal late complication after prolonged ...
Researchers at Dresden University Hospital may have discovered a new therapeutic approach for treating myelodysplastic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “It looks like, in the low-risk [myelodysplastic ...
Innovative models of germline genetic evaluation are needed for patients with MDS/AML to address systems-level barriers to care, including the development of inpatient genetic counseling and testing ...
BACKGROUND. Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to Acute Myeloid Leukemia (AML). Given ...
Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine ...
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of ...
Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results